P
Panayiotis G. Vlachoyiannopoulos
Researcher at National and Kapodistrian University of Athens
Publications - 139
Citations - 11053
Panayiotis G. Vlachoyiannopoulos is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Antiphospholipid syndrome & Medicine. The author has an hindex of 38, co-authored 117 publications receiving 9414 citations. Previous affiliations of Panayiotis G. Vlachoyiannopoulos include University of Pisa.
Papers
More filters
Journal ArticleDOI
Congruence and Complementarity of Differential Mobility Spectrometry and NMR Spectroscopy for Plasma Lipidomics
M. Ghorasaini,K. Tsezou,Aswin Verhoeven,Yassene Mohammed,Panayiotis G. Vlachoyiannopoulos,Emmanuel Mikros,Martin Giera +6 more
TL;DR: In this article , a combined workflow for subsequent NMR and MS-based analysis on single sample aliquots of human plasma was developed to facilitate a better understanding of patho-physiological lipoprotein and lipid alterations.
Book ChapterDOI
Rheumatic Disorders Associated with Metabolic, Endocrine, and Hematological Diseases
TL;DR: In patients with hyperthyroidism, rheumatic manifestations include osteoporosis, painless proximal muscle weakness, thyroid acropathy, and adhesive shoulder capsulitis, in patients with thyroiditis.
Journal ArticleDOI
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
Petros P. Sfikakis,Dimitrios Vassilopoulos,Gikas Katsifis,G. Vosvotekas,Theodoros Dimitroulas,Prodromos Sidiropoulos,P. Vounotrypidis,Dimitrios P. Bogdanos,Athanasios Georgountzos,A. Bounas,Panagiotis Georgiou,Souzana Gazi,Evangelia Kataxaki,Stamatis-Nick C. Liossis,Evangelos Theodorou,Charalampos Papagoras,Evangelos Theotikos,Panayiotis G. Vlachoyiannopoulos,Paraskevi V. Voulgari,Angeliki Kekki,Nikolaos Antonakopoulos,Dimitrios T. Boumpas +21 more
TL;DR: In this article , the effect of apremilast on patients with early peripheral PsA in terms of disease activity, clinical manifestations, patient-perceived outcomes, as well as the safety profile in routine care settings of Greece was evaluated.
Journal ArticleDOI
Incidence of autoantibodies related to systemic autoimmunity in patients with severe COVID-19 admitted to the intensive care unit.
Kleopatra Bitzogli,Edison Jahaj,Athanasios Dimitrios Bakasis,Efstathia K. Kapsogeorgou,Andreas V. Goules,Ioanna Stergiou,Vasileios C. Pezoulas,Christina Antoniadou,Panagiotis Skendros,Konstantinos Ritis,Dimitrios I. Fotiadis,Anastasia Kotanidou,Athanasios G. Tzioufas,Panayiotis G. Vlachoyiannopoulos +13 more
TL;DR: No correlation was found between AAbs and disease outcome and patients with severe COVID-19 express AAbs more commonly compared to controls, and AAbs were not found to correlate with the clinical outcome.
Journal ArticleDOI
Late and booster anti‐SARS‐CoV‐2 humoral responses in nonresponder vaccinated patients with rheumatic diseases receiving mycophenolate or rituximab: comment on the article by XXX et al
Athanasios Dimitrios Bakasis,Andreas V. Goules,Panayiotis G. Vlachoyiannopoulos,Kleopatra Bitzogli,Athanasios G. Tzioufas +4 more
TL;DR: In this paper , patients with systemic autoimmune rheumatic diseases (SARD) receiving immunosuppressive treatment with mycophenolate mofetil (MMF) or rituximab (RTX) exhibit altered antibody responses to SARS-CoV-2 vaccination.